FLASCO

Genomic Health Introduces New Diagnostic Test Oncotype AR-V7

  • Katrina Williams
  • April 17, 2019
  • The Oncotype DX AR-V7 Nucleus Detect® Assay is the first and only nuclear-localized AR-V7 liquid biopsy blood test that can help guide treatment decisions for patients diagnosed with mCRPC who have received and failed an AR-targeted therapy such as XTANDI® (enzalutamide), ZYTIGA® (abiraterone), or ERLEADA™ (apalutamide).
  • The Oncotype DX AR-V7 Nucleus Detect test can help guide next treatment decisions for mCRPC patients that have failed at least one AR-targeted drug. This test is covered by Medicare and through Medicare coverage, an estimated 25,000 mCRPC patients can benefit from knowing their AR-V7 status to help guide next treatment decisions after AR-targeted therapy failure. The Oncotype DX AR-V7 Nucleus Detect test is available nationwide in the U.S., and it is estimated that 50,000 men with mCRPC could benefit from knowing their AR-V7 status prior to selecting further treatment. link for our Medicare approval. – https://www.genomichealth.com/en-US/Advocacy/ARV7_Medicare_Coverage
  • For more information follow this link: https://www.genomichealth.com/en-US/Advocacy/ARV7_Nucleus_Detect_Test

Who’s Online

Profile picture of FLASCO